ADVERTISEMENT

Motilal Oswal: Cipla - Product Mix, Better Operating Leverage Propels Q2 Earnings  

Motilal Oswal: Cipla - Product Mix, Better Operating Leverage Propels Q2 Earnings

Employees package vaccine vials into boxes at a pharmaceutical plant in Pune. (Photographer Sanjit Das/Bloomberg)
Employees package vaccine vials into boxes at a pharmaceutical plant in Pune. (Photographer Sanjit Das/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Cipla Ltd. delivered record Q2 FY21 earnings, led by healthy growth across key markets and controlled operating cost.

The company is progressing well on:

  1. increasing market share in complex generics,
  2. adoption of digital transformation in domestic formulation segment,
  3. ensuring adequate availability of key raw materials, and
  4. improving operating leverage.

Click on the attachment to read the full report:

Motilal Oswal Cipla Q2FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.